.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
DAPA-HF tested dapagliflozin in patients with HFrEF, including individuals with and without diabetes. The randomized trial showed that adding dapagliflozin to standard therapy significantly reduced the composite of worsening heart failure or cardiovascular death compared with placebo. Importantly, the benefit was observed irrespective of diabetes status, reinforcing the concept that SGLT2 inhibition has become a heart-failure therapy rather than a diabetes-only intervention. For general physicians, this is especially relevant because many HFrEF patients are managed across internal-medicine and cardiology interfaces. The treatment decision should therefore be integrated into a broader GDMT pathway that also addresses renin–angiotensin system blockade, beta-blockade and mineralocorticoid receptor antagonism. Adverse effects, volume status, renal function and the patient's ability to maintain therapy should be considered. The DAPA-HF findings also illustrate the modern shift from treating isolated risk factors to targeting disease pathways that influence hospitalization and survival. In practice, the challenge is often not identifying evidence-based agents but initiating them early, titrating when tolerated and coordinating follow-up so that the patient receives the full therapeutic benefit.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
DAPA-HF tested dapagliflozin in patients with HFrEF, including individuals with and without diabetes. The randomized trial showed that adding dapagliflozin to standard therapy significantly reduced the composite of worsening heart failure or cardiovascular death compared with placebo. Importantly, the benefit was observed irrespective of diabetes status, reinforcing the concept that SGLT2 inhibition has become a heart-failure therapy rather than a diabetes-only intervention. For general physicians, this is especially relevant because many HFrEF patients are managed across internal-medicine and cardiology interfaces. The treatment decision should therefore be integrated into a broader GDMT pathway that also addresses renin–angiotensin system blockade, beta-blockade and mineralocorticoid receptor antagonism. Adverse effects, volume status, renal function and the patient's ability to maintain therapy should be considered. The DAPA-HF findings also illustrate the modern shift from treating isolated risk factors to targeting disease pathways that influence hospitalization and survival. In practice, the challenge is often not identifying evidence-based agents but initiating them early, titrating when tolerated and coordinating follow-up so that the patient receives the full therapeutic benefit.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
